Business
Nexien BioPharma Announces Acceptance of Patent Application No. 238946 by Israeli Patent Office
Nexien BioPharma Announces Acceptance of Patent Application No. 238946 by Israeli Patent Office.
About this update from Nexien Biopharma, Inc.
[{"type":"text","content":"\n \n Nexien BioPharma, Inc. (“Nexien” or the “Company”) (OTCQB: NXEN), a next \n generation biopharmaceutical company focused on research, development \n and commercialization of novel FDA-compliant cannabinoid pharmaceuticals \n and related drug delivery systems, today announced that its patent \n application No. 238946 for “Use of Cannabinoids and Terpenes for \n Treatment of Organophosphate and Carbamate Toxicity” has been accepted \n by the Israeli Patent Office. This application relates to pharmaceutical \n formulation compositions and their method of use in which isolated \n cannabinoid receptor modulators are optionally combined with terpene \n blends in a pharmaceutically acceptable carrier to treat or prevent \n disorders caused by exposure to an organophosphate or carbamate \n acetylcholinesterase inhibitor.\n \n \n The endocannabinoid system and other physiological systems can \n potentially mitigate the effects of organophosphate and carbamate \n toxicity when treated with medicaments affecting these systems in a time \n and dose-dependent format.\n \n \n Nexien’s unique process for treating symptoms incorporates a composition \n comprising tetrahydrocannabinol and cannabidiol formulated for \n administration by an oral, nasal, buccal, sublingual, parenteral, or any \n combination thereof.\n \n \n According to the Notification of Acceptance issued by the Israel Patent \n Office, examination of the application is completed and the application \n has been accepted. Pursuant to several administrative procedures, it is \n anticipated that a patent could transition from accepted to granted in \n the coming months.\n \n \n Alex Wasyl, Nexien’s Chief Executive Officer, stated, “Clinical \n investigation of advanced cannabinoid drug formulations and delivery \n systems could allow for significant advantages when compared with \n existing standard of care options for organophosphate and carbamate \n nerve agent exposure and resultant neurological and systemic toxicity. \n As bio-warfare becomes an increasing concern around the world, \n cannabinoid drug formulations could be a viable stand-alone or adjunct \n treatment option to provide patients with fewer side effects and thus an \n accelerated return to full functionality, whether soldiers or civilians.\"\n \n \n About ...